Literature DB >> 8200990

Cyclic AMP selectively enhances bradykinin receptor synthesis and expression in cultured arterial smooth muscle. Inhibition of angiotensin II and vasopressin response.

B S Dixon1.   

Abstract

Bradykinin receptors on vascular smooth muscle may play an important role in regulating the endogenous effects of the vascular kallikrein-kinin system. The present study examined the effect of cyclic nucleotides on bradykinin-stimulated responses in cultured arterial smooth muscle cells. Short term stimulation (1 min) with cyclic AMP produced a variable inhibition of bradykinin-stimulated calcium mobilization which was lost in later passaged cells. However, long-term stimulation (24 h) produced a consistent increase in bradykinin-stimulated calcium mobilization in both early and late passaged cells. Further analysis demonstrated that chronic exposure to cAMP produced a twofold increase in both the number of cell surface bradykinin receptors and in bradykinin-stimulated phosphoinositide hydrolysis. The increase in bradykinin receptors was time dependent (> 7 h) and blocked by protein synthesis inhibitors, suggesting that cAMP enhanced the synthesis of new bradykinin receptors. The increase in bradykinin receptor binding and calcium mobilization was also stimulated by cholera toxin, forskolin, and isobutylmethylxanthine, but not isoproterenol or prostaglandin E2. Of considerable interest, prolonged exposure to cAMP inhibited both angiotensin II and arginine vasopressin-stimulated phosphoinositide hydrolysis and intracellular calcium mobilization. In summary, prolonged treatment with cAMP selectively stimulates the synthesis and expression of bradykinin receptors on arterial smooth muscle while decreasing the responsiveness to vasoconstrictor agonists such as angiotensin II and vasopressin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200990      PMCID: PMC294477          DOI: 10.1172/JCI117264

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

Review 1.  Inositol phosphate biochemistry.

Authors:  P W Majerus
Journal:  Annu Rev Biochem       Date:  1992       Impact factor: 23.643

Review 2.  Regulators and effectors of ras proteins.

Authors:  G Bollag; F McCormick
Journal:  Annu Rev Cell Biol       Date:  1991

3.  Bradykinin receptor-like binding studied with iodinated analogues.

Authors:  C E Odya; T L Goodfriend; C Peña
Journal:  Biochem Pharmacol       Date:  1980-02       Impact factor: 5.858

4.  Kallikrein messenger RNA in rat arteries and veins.

Authors:  G M Saed; O A Carretero; R J MacDonald; A G Scicli
Journal:  Circ Res       Date:  1990-08       Impact factor: 17.367

5.  Expression cloning of a rat B2 bradykinin receptor.

Authors:  A E McEachern; E R Shelton; S Bhakta; R Obernolte; C Bach; P Zuppan; J Fujisaki; R W Aldrich; K Jarnagin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

6.  Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation.

Authors:  R D Farhy; O A Carretero; K L Ho; A G Scicli
Journal:  Circ Res       Date:  1993-06       Impact factor: 17.367

7.  Bradykinin and angiotensin II: activation of protein kinase C in arterial smooth muscle.

Authors:  B S Dixon; R V Sharma; T Dickerson; J Fortune
Journal:  Am J Physiol       Date:  1994-05

8.  Increases in endothelial cyclic AMP levels amplify agonist-induced formation of endothelium-derived relaxing factor (EDRF).

Authors:  W F Graier; K Groschner; K Schmidt; W R Kukovetz
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

9.  Effect of H-8, an isoquinolinesulfonamide inhibitor of cyclic nucleotide-dependent protein kinase, on cAMP- and cGMP-mediated vasorelaxation.

Authors:  J T Daugirdas; H L Zhou; V V Tamulaitis; C W Nutting; R R Fiscus
Journal:  Blood Vessels       Date:  1991

10.  Actions of bradykinin on isolated cerebral and peripheral arteries.

Authors:  N Toda
Journal:  Am J Physiol       Date:  1977-03
View more
  2 in total

1.  Kallistatin is a potent new vasodilator.

Authors:  J Chao; J N Stallone; Y M Liang; L M Chen; D Z Wang; L Chao
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 2.  Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology.

Authors:  Cheryl L Holmes; Donald W Landry; John T Granton
Journal:  Crit Care       Date:  2003-06-26       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.